2026-04-17T01:41:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/211362025-12-13T20:52:36Zcom_2072_6col_2072_452954

00925njm 22002777a 4500 dc Domingo Espinós, Júlia, 1991- author 2013-09-30T15:15:22Z 2013-09-30T15:15:22Z 2013-09-30 Treball de fi de grau en Biologia Humana Supervisors: Jordi Garcia Ojalvo i/nElena Abad Multiple Sclerosis is the most common non-traumatic cause of neurological/ndisability in young people. There is no cure yet, and until recently, few long-term/ntherapies existed. Interferon beta (IFNβ) was the first treatment, and remains the most/ncommonly prescribed. One of the most significant problems of IFNβ therapy is the/nproduction of drug specific antibodies. Up to 45% of patients develop neutralizing/nantibodies (NAbs) to IFNβ products. The neutralizing antibody binds to the biological/nagent preventing its interaction with its receptor, inhibiting the biological action of the/nprotein, which abrogates the clinical efficacy of IFNβ treatment. Interferon-beta/nmediates its response by binding to its high affinity cell surface receptor and initiating/nthe JAK/STAT signalling cascade. In this project we have analyzed the IFNβ signaling/npathway in macrophages when neutralizing antibodies are present. The response to/nthis pathway after IFNβ stimulation shows a transient oscillatory rhythm of STAT1/nphosphorylation, which varies as NAbs concentration increases. To improve our/nunderstanding of that behavior, we extended an existing mathematical model based on/nnonlinear ordinary differential equations of JAK/STAT pathway by including IFN-NAb/nassociation and IFN-activation receptor. Combining our theoretical model with/nexperimental data we could study the role of neutralizing antibodies on the molecular/nresponse and determine its lifetime after cytokine stimulation. Esclerosi múltiple Treball de fi de grau -- Curs 2012-2013 Neutralizing antibodies in Multiple Sclerosis a model-based analysis of Interferon beta signaling pathway in macrophages